

Edgar Filing: - Form

Form

Unknown document format

1.25; MARGIN-RIGHT: 0pt" align="justify">

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

EXHIBIT INDEX

Exhibit

Number Description of Exhibit

99.1 VIREXX COMPLETES TREATMENT IN HEPAVAXX B VACCINE PHASE I STUDY

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VIREXX MEDICAL CORP.

VIREXX MEDICAL CORP.

Date: August 9, 2006

Date: August 9, 2006

/s/ Scott Langille

/s/ Tracy Smith

Scott Langille
Chief Financial Officer

Tracy Smith
Manager of Finance